Anzeige
Mehr »
Login
Donnerstag, 23.05.2024 Börsentäglich über 12.000 News von 688 internationalen Medien
Mit dieser Aktie könntest Du von der Cannabis-Legalisierungswelle profitieren!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A14V4E | ISIN: BE0974283153 | Ticker-Symbol: 1TM
Lang & Schwarz
22.05.24
22:58 Uhr
0,217 Euro
0,000
0,00 %
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
MITHRA PHARMACEUTICALS SA Chart 1 Jahr
5-Tage-Chart
MITHRA PHARMACEUTICALS SA 5-Tage-Chart
RealtimeGeldBriefZeit
0,2140,22122.05.
0,0000,00022.05.

Aktuelle News zur MITHRA PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
03.05.Mithra Pharmaceuticals: Mithra enters into exclusive negotiations with Gedeon Richter and secures continued funding in the context of its monetization process199Liege, Belgium, 3 May 2024 - 17:30 CEST - Mithra (Euronext Brussels: MITRA), a company dedicated to women's health, today announces that, after diligent evaluation of several binding offers, Mithra...
► Artikel lesen
29.04.XFRA 1TM: AUSSETZUNG/SUSPENSION216DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILMITHRA PHARMACEUTIC.AIW...
► Artikel lesen
29.04.Mithra Pharmaceuticals: Mithra updates on offers received in the context of its monetization process and on its Annual Report 20237
22.04.Mithra Pharmaceuticals: Mithra secures court protection measures to advance monetization process174Court Grants "Transfer under Judicial Supervision" for CDMO facility, safeguarding Mithra's activities and expediting the M&A process for its Contract Development and Manufacturing Organization.Approval...
► Artikel lesen
18.04.Estetrol by Mithra Pharmaceuticals for Genitourinary Syndrome of Menopause (GSM): Likelihood of Approval5
18.04.Estetrol by Mithra Pharmaceuticals for Female Sexual Dysfunction: Likelihood of Approval4
08.03.Mithra slips on low Estelle sales, slow monetisation20
08.03.Mithra Pharmaceuticals: Mithra reports full year 2023 financial results694Mithra reports full year 2023 financial results Revenues were EUR 40.2 million, down from the 2022 result of EUR 67.0 million which was positively impacted by exceptional upfront cash payments from...
► Artikel lesen
05.03.Mithra Pharmaceuticals: Mithra initiates monetization process, receives bridge loan from existing lenders501Mithra initiates monetization process, receives bridge loan from existing lenders Mithra appoints advisors and initiates a process to monetize its assets or execute a sale of its businessMithra...
► Artikel lesen
05.03.Mithra Pharmaceuticals: Mithra announces changes to its executive management577Mithra announces changes to its executive management Liege, Belgium, 05 March 2024 - 07:00 CET - Mithra (Euronext Brussels: MITRA), a company dedicated to women's health, today announces the termination...
► Artikel lesen
29.02.Mithra Pharmaceuticals: DONESTA® safety study for menopause completes treatment phase and advances to data management & reporting phase412DONESTA® safety study for menopause completes treatment phase and advances to data management & reporting phase Mithra on-track for completion of Phase 3 study for DONESTA® to treat...
► Artikel lesen
15.02.Mithra sells position in Mayne Pharma to free up cash6
15.02.Mithra Pharmaceuticals: Mithra sells shares in Mayne Pharma502Mithra sells shares in Mayne Pharma Mithra sold all 4,221,815 shares it held in Mayne Pharma for EUR ~12.8 millionAs the Mayne Pharma shares were pledged to the secured lenders of...
► Artikel lesen
06.02.Mithra sets out plan to rescue cash runway15
06.02.Mithra Pharmaceuticals: Mithra updates on cash position469Mithra updates on cash position Mithra's current cash of EUR 6.5 million is expected to cover its current cash runway through early MarchMithra is actively engaging with stakeholdersMithra...
► Artikel lesen
21.12.23Mithra Pharmaceuticals: Mithra and Rafa Laboratories sign binding Head of Terms to commercialize DONESTA® in Israel1.407Mithra and Rafa Laboratories sign binding Head of Terms to commercialize DONESTA® in Israel Rafa Laboratories to receive the exclusive commercial rights for DONESTA® in Israel on...
► Artikel lesen
20.12.23Mithra Pharmaceuticals: Mithra Completes Pediatric Study of ESTELLE® in Adolescent Patients521Mithra Completes Pediatric Study of ESTELLE® in Adolescent Patients Important milestone for Mithra's commitment to bring benefits of ESTELLE® to more womenPotential EMA approval in pediatric...
► Artikel lesen
18.12.23Mithra Reports Positive Review From DSMB On European Phase 3 Program For DONESTA4
18.12.23Mithra Pharmaceuticals: Mithra Receives Positive DSMB Opinion on DONESTA® European Phase 3 Trial332Mithra Receives Positive DSMB Opinion on DONESTA® European Phase 3 Trial The DSMB recommends continuing the phase 3 trial in Europe following regular safety assessmentThe menopause phase 3...
► Artikel lesen
04.12.23Mithra: Gedeon Richter To Have Commercial Rights For ESTELLE, DONESTA In China5
Seite:  Weiter >>
56 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1